Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C, Chronic Eighteen years of age or older at screening. 2. Female study participants with childbearing potential (as defined below) and all males must be willing to practice either Abstinence from sexual intercourse or One or more forms of effective barrier contraception throughout dosing and for 30 days following the last dose. This cannot hormonal contraception for female subjects. Effective forms of barrier contraception a male condom with spermicide use by female sexual partner of a female condom with spermicide Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) includes any female who Has had a hysterectomy or Has had a bilateral oophorectomy (ovariectomy) or Is post-menopausal (a demonstration of a total cessation of menses for greater than or equal to1 year) Has had a bilateral tubal ligation or fallopian tube inserts 3. Chronic HCV GT-1 or GT-4 infection as documented by greater than or equal to 1 measurement of serum HCV RNA greater than or equal to 2,000 international units per milliliter during screening and at least one of the following A positive anti-HCV antibody, HCV RNA, or HCV genotype test result greater than or equal to 12 months prior to the baseline (day 0) visit together with current positive HCV RNA and anti-HCV antibody test results or  Current or prior history of any of the following Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug Poor venous access interfering with required study blood collection Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage) Solid organ transplantation Significant pulmonary disease, significant cardiac disease or porphyria Unstable psychiatric disease (Subjects with psychiatric illness that is well-controlled on a stable treatment regimen or currently not requiring medication may be included) Any malignancy or its treatment that in the opinion of the PI may cause ongoing interference with host immunity; subjects under evaluation for malignancy are not eligible Significant drug allergy (such as anaphylaxis or hepatotoxicity)